HFZS
839725
Hangzhou SDIC Microelectronics Inc.
688130
Henan Liliang Diamond
301071
Sf Diamond Co., Ltd.
300179
Jiangsu Zhengdan Chemical Industry
300641
CN Stock MarketDetailed Quotes
688443 Chongqing Genrix Biopharmaceutical
- 26.87
- -0.69-2.50%
Market Closed Dec 23 15:00 CST
9.85BMarket Cap-12.64P/E (TTM)
27.57High26.56Low10.83KlotVolume27.56Open27.56Pre Close29.34MTurnover0.95%Turnover RatioLossP/E (Static)366.68MShares45.5152wk High4.19P/B3.06BFloat Cap22.1152wk Low33.07Limit Up114.04MShs Float45.51Historical High22.05Limit Down3.67%Amplitude22.11Historical Low--Dividend TTM27.10Avg Price5.12KlotAsk--Div YieldTTM100Lot Size4.89KlotBid
Chongqing Genrix Biopharmaceutical Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 8,875.43%12.49M | -90.47%12.66K | -93.67%6.33K | 154.92%1.21M | -69.59%139.13K | -70.57%132.8K | 1,479.93%100.01K | -98.79%475.24K | 148.83%457.59K | 451.26K |
| Operating revenue | 8,875.43%12.49M | -90.47%12.66K | -93.67%6.33K | 154.92%1.21M | -69.59%139.13K | -70.57%132.8K | 1,479.93%100.01K | -98.79%475.24K | 148.83%457.59K | --451.26K |
| Total operating cost | -2.44%561.97M | -7.28%363.52M | -18.53%164.59M | 26.40%815.12M | 25.71%576M | 48.51%392.06M | 143.25%202.04M | 72.72%644.89M | 458.21M | 264M |
| Operating cost | 2,294.25%2.42M | -95.59%4.36K | -97.73%2.18K | 39.78%739.8K | -80.66%101.06K | -80.42%98.88K | 4,298.32%95.92K | -97.27%529.27K | --522.43K | --505.01K |
| Operating tax surcharges | 22.05%2.05M | 20.32%1.35M | 21.76%675.29K | -10.17%2.56M | -9.62%1.68M | -13.53%1.12M | -23.73%554.6K | 7.31%2.85M | --1.86M | --1.3M |
| Operating expense | 3,870.00%69.21M | 12,257.38%36.97M | --12.4M | --10.43M | --1.74M | --299.17K | ---- | ---- | ---- | ---- |
| Administration expense | -21.93%94.44M | -26.45%61.88M | -39.59%27.9M | 6.34%163.36M | 13.51%120.97M | 37.88%84.14M | 267.84%46.18M | 534.37%153.62M | --106.57M | --61.02M |
| Financial expense | -370.29%-44.1M | -213.99%-20.24M | -172.30%-6.31M | -47.18%17.64M | -33.92%16.31M | 13.77%17.76M | 21.39%8.73M | 5.06%33.4M | --24.69M | --15.61M |
| -Interest expense (Financial expense) | -25.68%20.61M | -28.23%13.12M | -20.60%7.03M | 6.84%34.99M | 16.86%27.73M | 20.39%18.28M | 21.93%8.86M | 1.01%32.75M | --23.73M | --15.19M |
| -Interest Income (Financial expense) | -461.35%-64.72M | -5,182.42%-33.37M | -22,497.04%-13.35M | -10,742.26%-17.46M | -10,853.62%-11.53M | -824.11%-631.72K | -58.13%-59.06K | 60.41%-161.07K | ---105.25K | ---68.36K |
| Research and development | 0.63%437.94M | -1.76%283.55M | -11.29%129.93M | 36.50%620.4M | 34.08%435.19M | 55.55%288.65M | 134.05%146.47M | 53.90%454.49M | --324.57M | --185.56M |
| Credit Impairment Loss | ---727.13K | 57.66%-633.03 | 94.39%-316.51 | ---- | ---- | 94.13%-1.5K | -1,534.23%-5.64K | ---- | ---1.04K | ---25.47K |
| Asset Impairment Loss | -110.63%-107.72K | -110.46%-86.47K | 90.16%-60.6K | 178.40%975.29K | 201.31%1.01M | 1,093.27%826.31K | -1,034.18%-615.67K | -364.69%-1.24M | ---1M | ---83.19K |
| Other net revenue | ||||||||||
| Fair value change income | -38.67%1.09M | ---- | ---- | -72.80%1.94M | -70.75%1.78M | -60.91%1.56M | -53.52%898.02K | 73.68%7.14M | --6.07M | --3.98M |
| Invest income | --11.12K | --11.12K | --11.12K | ---- | ---- | ---- | ---- | 3,324.24%719.73K | --719.73K | --719.73K |
| Asset deal income | ---1.75K | ---1.75K | ---- | ---- | ---- | ---- | ---- | --475.24 | --475.24 | ---- |
| Other revenue | -29.54%3.41M | 18.03%1.65M | 25.65%874.47K | -84.25%9.68M | 120.18%4.84M | 3.51%1.4M | 0.16%695.96K | 614.97%61.44M | --2.2M | --1.35M |
| Operating profit | 3.95%-545.81M | 6.76%-361.93M | 18.51%-163.76M | -39.03%-801.32M | -26.34%-568.23M | -50.68%-388.15M | -149.71%-200.96M | -79.16%-576.36M | -93.08%-449.77M | -257.6M |
| Add:Non operating Income | ---- | ---- | ---- | 3,058,314.12%26K | ---- | ---- | ---- | -99.85%0.85 | --0.85 | --0.85 |
| Less:Non operating expense | 5,647.06%535.97K | -11.79%4.62K | 44.73%6.16K | 1,517.98%29.41K | 438.16%9.33K | 212.49%5.24K | --4.26K | -99.58%1.82K | --1.73K | --1.68K |
| Total profit | 3.85%-546.34M | 6.76%-361.93M | 18.51%-163.77M | -39.03%-801.32M | -26.34%-568.24M | -50.68%-388.15M | -149.72%-200.97M | -78.92%-576.37M | -92.73%-449.77M | -257.61M |
| Net profit | 3.85%-546.34M | 6.76%-361.93M | 18.51%-163.77M | -39.03%-801.32M | -26.34%-568.24M | -50.68%-388.15M | -149.72%-200.97M | -78.92%-576.37M | -92.73%-449.77M | -257.61M |
| Net profit from continuing operation | 3.85%-546.34M | 6.76%-361.93M | 18.51%-163.77M | -39.03%-801.32M | -26.34%-568.24M | -50.68%-388.15M | -149.72%-200.97M | -78.92%-576.37M | ---449.77M | ---257.61M |
| Net profit of parent company owners | 3.85%-546.34M | 6.76%-361.93M | 18.51%-163.77M | -39.03%-801.32M | -26.34%-568.24M | -50.68%-388.15M | -149.72%-200.97M | -78.92%-576.37M | -92.73%-449.77M | ---257.61M |
| Earning per share | ||||||||||
| Basic earning per share | 19.89%-1.49 | 29.79%-0.99 | 38.36%-0.45 | -19.05%-2.5 | -13.41%-1.86 | -50.00%-1.41 | -151.72%-0.73 | -79.49%-2.1 | ---1.64 | ---0.94 |
| Diluted earning per share | 19.89%-1.49 | 29.79%-0.99 | 38.36%-0.45 | -19.05%-2.5 | -13.41%-1.86 | -50.00%-1.41 | -151.72%-0.73 | -79.49%-2.1 | ---1.64 | ---0.94 |
| Other composite income | ||||||||||
| Total composite income | 3.85%-546.34M | 6.76%-361.93M | 18.51%-163.77M | -39.03%-801.32M | -26.34%-568.24M | -50.68%-388.15M | -149.72%-200.97M | -78.92%-576.37M | -449.77M | -257.61M |
| Total composite income of parent company owners | 3.85%-546.34M | 6.76%-361.93M | ---- | ---- | -26.34%-568.24M | -50.68%-388.15M | ---- | ---- | ---449.77M | ---257.61M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | -- | -- | -- |
| Auditor | -- | -- | -- | Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
